食管癌同期放化疗中脂质体紫杉醇与游离紫杉醇联合顺铂的对照研究  

A case-control study of paclitaxel liposome and free paclitaxel respectively combined with cisplatin in concurrent chemoradiotherapy for esophageal cancer

作　　者：孙荣刚[1] 郑安平[1] 张光斌[1] 

机构地区：[1]河南省安阳市肿瘤医院放疗一科,河南安阳455000

出　　处：《实用医院临床杂志》2015年第4期60-62,共3页Practical Journal of Clinical Medicine

摘　　要：目的探讨食管癌同期放化疗中应用脂质体紫杉醇联合顺铂的临床疗效及安全性。方法 92例同期放化疗的食管癌患者,其中46例采用脂质体紫杉醇+顺铂化疗(A组),46例采用紫杉醇+顺铂化疗(B组)。比较两组患者的近期疗效、远期疗效及不良反应。结果两组近期有效率、1年生存率、2年生存率比较,差异均无统计学意义(P>0.05);A组神经毒性、过敏及关节/肌肉痛发生率明显低于B组,差异有统计学意义(P<0.01)。结论与紫杉醇相比,食管癌同期放化疗中应用脂质体紫杉醇联合顺铂疗效较好,紫杉醇相关不良反应低,值得临床进一步研究及推广应用。Objective To investigate the efficacy and safety of paclitaxel liposome combined with cisplatin in concurrent chemoradiotherapy for esophageal cancer.Methods Clinical data of 92 patients with esophageal cancer who accepted concurrent chemoradiotherapy were analyzed.The patients were divided into two groups according to the different chemotherapy schemes.The group A（n =46） was treated with paclitaxel liposome combined with cisplatin while the group B（n = 46） was treated with paclitaxel combined with cisplatin.Short-term efficacy,long-term efficacy and adverse reaction were compared between the two groups.Results There was no significant difference in short-term effective rate and 1-and 2-year survival rate between the two groups（P 〉0.05）.However,the group A showed better efficacy than the group B in recurrence rate of neurotoxicity,allergic reactions and joint muscle pain（P〈 0.01）.Conclusion Compared to the paclitaxel combined with cisplatin,the paclitaxel liposome combined with cisplatin shows better efficacy and less adverse reaction in concurrent chemoradiotherapy for esophageal cancer.It is worthy of further clinic study,popularization and application.

关 键 词：食管癌 同期放化疗 紫杉醇 脂质体 

分 类 号：R730.5[医药卫生—肿瘤]